[Hypolipidemic, hypocholesterolemic and antisclerotic action of the rotenoid glycoside amorphin].
Amorphin--24-vicyanoside (C34H4O16(2)H2O)--in a dose of 10 mg/kg orally decreases the content of cholesterol, total lipids, atherogenic lipoproteids in the blood and organs of intact rats and rats with endogenous or ethanol hyperlipemia, inhibits the development of experimental atherosclerosis in rabbits induced by the combination of risk factors (cholesterol + glucose + hypodynamia), decreases the content of lipids in the blood and organs (especially in aorta), prevents the development of morphological manifestations of the aorta atherosclerosis.
D000818:Animals; D001161:Arteriosclerosis / Q000097:blood / Q000188:drug therapy*; D002784:Cholesterol / Q000097:blood; D004353:Drug Evaluation, Preclinical; D005260:Female; D005419:Flavonoids / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D011817:Rabbits; D051381:Rats
D005419:Flavonoids; D000960:Hypolipidemic Agents; D008055:Lipids; C049147:amorphin flavonoid; D002784:Cholesterol
O gipolipidemicheskom, gipokholesterinemicheskom i antiskleroticheskom deĭstvii rotenoidnogo glikozida amorfina.